No wonder my IBS got better when I was on Metformin. I may try to start "Metformin Synergy" from Empower Pharmacy with Leucine and low dose sildenafil (yes, Viagra) to see if I do not lose muscle pump or get tired like I did with Metformin monotherapy 500 mg twice per day. I could use losing a few of my quarantine pounds also. These are not human studies but...
Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer - PubMedThese results indicate that metformin suppresses NF-κB activation in intestinal epithelial cells and ameliorates murine colitis and colitis-associated tumorigenesis in mice, suggesting that metformin could be a potential therapeutic agent for the treatment of inflammatory bowel disease.pubmed.ncbi.nlm.nih.gov
Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg BalanceObjective Metformin is used to treat type 2 diabetes. We sought to determine whether metformin reduces inflammation, by regulating p-signal transducer and activator of transcription 3 (STAT3) expression and T-helper 17 (Th17) cell proliferation, in a mouse model of inflammatory bowel disease...journals.plos.org
Love Affair With Metformin: Still Strong, or Time to Move On?
.... "at $4 a month," it's hard to argue with the economics, she noted.
Newer drugs that have shown benefit in cardiovascular outcomes trials include the SGLT-2 inhibitors empagliflozin (Jardiance, Boehringer Ingelheim) in EMPA-REG OUTCOME and canagliflozin (Invokana, Johnson & Johnson) in CANVAS, and the GLP-1 agonists liraglutide (Victoza, Novo Nordisk) in LEADER and semaglutide (Ozempic, Novo Nordisk) in SUSTAIN-6.
But these studies were mainly conducted in patients with high-risk type 2 diabetes who had a long duration of disease and already had cardiovascular disease (CVD) or a number of risk factors for it.
"So these data do not directly translate to 87% of our population," requiring first-line therapy for type 2 diabetes, Aroda argued.
She also pointed to safety, acknowledging, "We all know the potential for gastrointestinal disturbances with metformin and B12 deficiency," but this pales in comparison to the numerous safety warnings issued for newer drugs over the past few years, she said."
..."metformin does not address many of the core pathophysiologies of type 2 diabetes, she argued, and secondly, "you do not improve metabolic parameters as well as other [drugs] can." Although metformin lowers HbA1c, it is fairly neutral when it comes to any benefits on weight, blood pressure, and lipids, for example."